Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results

Int J Antimicrob Agents. 2020 Nov;56(5):106136. doi: 10.1016/j.ijantimicag.2020.106136. Epub 2020 Aug 8.

Abstract

During the Covid-19 pandemic, many intensive care unit (ICU) patients received hydroxychloroquine. The primary objective of this study was to assess the effects of hydroxychloroquine according to its plasma concentration in ICU patients. A single-center retrospective study was performed from March to April 2020 in an ICU of a university hospital. All patients admitted to the ICU with confirmed Covid-19 pneumonia and treated with hydroxychloroquine were included. The study compared 17 patients in whom the hydroxychloroquine plasma concentration was in the therapeutic target (on-target) and 12 patients in whom the plasma concentration was below the target (off-target). The follow-up of patients was 15 days. No association was found between hydroxychloroquine plasma concentration and viral load evolution (P = 0.77). There was no significant difference between the two groups for duration of mechanical ventilation, length of ICU stay, in-hospital mortality, and 15-days mortality. These findings indicate that hydroxychloroquine administration for Covid-19 patients hospitalized in ICU is not associated with improved outcomes. Larger multicenter studies are needed to confirm these results.

Keywords: Covid-19 pneumonia; Hydroxychloroquine; Intensive care unit.

Publication types

  • Observational Study

MeSH terms

  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / blood
  • Anti-Inflammatory Agents / therapeutic use*
  • Betacoronavirus / drug effects*
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / drug therapy*
  • Critical Care
  • Female
  • Hospital Mortality
  • Humans
  • Hydroxychloroquine / adverse effects
  • Hydroxychloroquine / blood
  • Hydroxychloroquine / therapeutic use*
  • Intensive Care Units
  • Length of Stay / statistics & numerical data
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Preliminary Data
  • Retrospective Studies
  • SARS-CoV-2
  • Viral Load / drug effects

Substances

  • Anti-Inflammatory Agents
  • Hydroxychloroquine